Komori
Management planning4527ROHTO PHARMACEUTICAL CO.,LTD.Pharmaceuticals

Notice Regarding Partial Corrections to the "Medium- to Long-Term Growth Strategy 2026"

Regarding the medium- to long-term growth strategy announced on 2 October 2026, wording that had stated the figures definitively as financial “targets” was revised to refer to “forecasts and outlook” reviewed on a rolling basis. The figures themselves, including sales and operating profit, have not been changed.

Worth reading
57In focus
Scored from 2 of 3 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
290
¥100 million (increase from the previous sales forecast; operating profit up ¥2.8 billion)
Wording
Avoiding a definitive answer
How definitive the wording is.

The document this correction applies to

Timely disclosure
"Medium- to Long-Term Growth Strategy 2026"2026-10-02

What was corrected and how

A subsequent correction by the company to the contents of an already published filing.

Original disclosure2 October 2026

Medium- to Long-Term Growth Strategy 2026

Open the original document
3 daysThe pre-correction wording stayed published for this period (Calculated from the Original Disclosure Date Indicated in the Document)
This correction2026-10-05
Location of correction (where in the original document)

Page 1, line 3; page 1, 1. Background to Formulation; page 2, 3. Financial Targets for 2031; page 2, 4. Relationship with the Previous Financial Forecast for 2030; page 2, 5. Policy on Shareholder Returns

Before correction

“Financial forecast with fiscal 2031 as the target year” / “We have set quantitative targets.” / “Financial targets for 2031” / “We will aim for a dividend payout ratio of 40%.” / The disclosure stated that the company aimed for sales of ¥415.0 billion, operating profit of ¥54.0 billion, an operating margin of 13%, and EBITDA of 18.2% for fiscal 2030; under this rolling update, these were revised to sales of ¥444.0 billion, operating profit of ¥56.8 billion, an operating margin of 12.8%, and EBITDA of 18.0%, and new targets of sales of ¥464.0 billion, operating profit of ¥59.8 billion, and an operating margin of 12.9% were set for fiscal 2031 / “Targets following this rolling update” / “We are targeting a DOE of at least 4.0%.”

After correction

“Financial forecast toward fiscal 2031” / “We have formulated an outlook.” / “Financial forecast for 2031” / “We forecast a dividend payout ratio of 40%.” / The disclosure stated that, compared with the previous forecast for fiscal 2030, sales were raised by ¥29.0 billion to ¥444.0 billion and operating profit by ¥2.8 billion to ¥56.8 billion, and that the new forecast for fiscal 2031 was sales of ¥464.0 billion, operating profit of ¥59.8 billion, and an operating margin of 12.9% / “Forecast following this rolling update” / “We expect DOE to be at the 4.0% level.”

ChangesWording such as “targets,” “aim,” and “revised” was changed to wording such as “forecasts,” “outlook,” and “raised,” on the premise of a rolling approach. For fiscal 2030, the figures are sales of ¥444.0 billion and operating profit of ¥56.8 billion, with the increases from the previous forecast explicitly stated as ¥29.0 billion for sales and ¥2.8 billion for operating profit.
Reason for correction

The company believes that, precisely because this is an era of rapid change and uncertainty, management forecasts need to be reviewed regularly, and therefore formulated forecasts and an outlook on a rolling basis rather than using fixed plan figures or target figures.

What was corrected and how
ItemDetails
Disclosure subject to correctionMedium- to Long-Term Growth Strategy 2026
Original disclosure date2 October 2026
Location of correctionPage 1, line 3; page 1, 1. Background to Formulation; page 2, 3. Financial Targets for 2031; page 2, 4. Relationship with the Previous Financial Forecast for 2030; page 2, 5. Policy on Shareholder Returns
Details of correction“Financial forecast with fiscal 2031 as the target year” / “We have set quantitative targets.” / “Financial targets for 2031” / “We will aim for a dividend payout ratio of 40%.” / The disclosure stated that the company aimed for sales of ¥415.0 billion, operating profit of ¥54.0 billion, an operating margin of 13%, and EBITDA of 18.2% for fiscal 2030; under this rolling update, these were revised to sales of ¥444.0 billion, operating profit of ¥56.8 billion, an operating margin of 12.8%, and EBITDA of 18.0%, and new targets of sales of ¥464.0 billion, operating profit of ¥59.8 billion, and an operating margin of 12.9% were set for fiscal 2031 / “Targets following this rolling update” / “We are targeting a DOE of at least 4.0%.” → “Financial forecast toward fiscal 2031” / “We have formulated an outlook.” / “Financial forecast for 2031” / “We forecast a dividend payout ratio of 40%.” / The disclosure stated that, compared with the previous forecast for fiscal 2030, sales were raised by ¥29.0 billion to ¥444.0 billion and operating profit by ¥2.8 billion to ¥56.8 billion, and that the new forecast for fiscal 2031 was sales of ¥464.0 billion, operating profit of ¥59.8 billion, and an operating margin of 12.9% / “Forecast following this rolling update” / “We expect DOE to be at the 4.0% level.”
Reason for correctionThe company believes that, precisely because this is an era of rapid change and uncertainty, management forecasts need to be reviewed regularly, and therefore formulated forecasts and an outlook on a rolling basis rather than using fixed plan figures or target figures.
Items this document does not state (1)
Impact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The company explained that, because management forecasts need to be reviewed regularly in an era of rapid change and uncertainty, it formulated forecasts and an outlook on a rolling basis rather than using fixed plan figures or target figures.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding Partial Corrections to the "Medium- to Long-Term Growth Strategy 2026" | ROHTO PHARMACEUTICAL CO.,LTD. (4527) timely disclosure | Komori